MBIO Stock Summary and Trading Ideas (Mustang Bio | NASDAQ:MBIO)

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Mustang Bio trades on the NASDAQ stock market under the symbol MBIO.

As of October 16, 2026, MBIO stock price declined to $0.38 with 29,315 million shares trading.

MBIO has a beta of 1.70, meaning it tends to be more sensitive to market movements. MBIO has a correlation of 0.11 to the broad based SPY ETF.

MBIO has a market cap of $2.85 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, MBIO traded as high as $105.50 and as low as $.37.

The top ETF exchange traded funds that MBIO belongs to (by Net Assets): VXF.

MBIO has underperformed the market in the last year with a price return of -75.2% while the SPY ETF gained +16.7%. MBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.6% and -20.1%, respectively, while the SPY returned +1.9% and -0.8%, respectively.

MBIO support price is $.36 and resistance is $.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MBIO shares will trade within this expected range on the day.